Payment overview · 2025
General Payments
$1,567.32
97 reported records · 21 companies
Healthcare provider profile · identity verified
Mitchell Frank Finnie, MD
Allopathic & Osteopathic Physicians|Family Medicine · SAN ANTONIO, TX · NPI 1245236231
Verified facts
What the public records show
CMS Open Payments records show Mitchell Frank Finnie, MD received $1,567.32 in general payments during 2025 across 97 reported records.
Amgen Inc. accounted for 19.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $298.08 | 19.0% | 33 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $276.08 | 17.6% | 20 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $203.36 | 13.0% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $96.17 | 6.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $83.53 | 5.3% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $79.23 | 5.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $74.01 | 4.7% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $63.40 | 4.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.19 | 3.2% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$49.30 | 3.1% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $44.25 | 2.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $44.19 | 2.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $38.42 | 2.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.42 | 2.3% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.00 | 2.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.71 | 1.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.25 | 1.0% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $15.35 | 1.0% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.32 | 1.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.83 | 0.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.23 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,558.42 | 96 |
| Education | $8.90 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $271.53 | 30 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $206.36 | 22 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $203.36 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $173.79 | 12 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $173.79 | 12 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $96.17 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $83.53 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $63.40 | 3 | 2025 |
Source payment records
|
|||||
| CATALYFT PL EXPANDABLE INTERBODY SYSTEM Normalized: catalyft pl expandable interbody system |
Device | Medtronic, Inc. | $49.30 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $44.25 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $44.19 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $38.42 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $36.42 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $36.42 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.31 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $36.00 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.29 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.29 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $35.22 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $34.21 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $27.26 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $26.55 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $25.06 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 50 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 120 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 193 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
120 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
193 | 44 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
55 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 926 | 303 |
| Levothyroxine Sodium | Levothyroxine Sodium | 644 | 181 |
| Atorvastatin Calcium | Atorvastatin Calcium | 329 | 108 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 322 | 104 |
| Montelukast Sodium | Montelukast Sodium | 266 | 94 |
| Tamsulosin Hcl | Tamsulosin Hcl | 254 | 85 |
| Escitalopram Oxalate | Escitalopram Oxalate | 227 | 75 |
| Losartan Potassium | Losartan Potassium | 212 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 204 | 60 |
| Lisinopril | Lisinopril | 203 | 67 |
| Prednisone | Prednisone | 203 | 156 |
| Azithromycin | Azithromycin | 199 | 157 |
| Fluticasone Propionate | Fluticasone Propionate | 198 | 88 |
| Ozempic | Semaglutide | 193 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 180 | 55 |
| Metformin Hcl Er | Metformin Hcl | 176 | 57 |
| Pioglitazone Hcl | Pioglitazone Hcl | 171 | 54 |
| Liothyronine Sodium | Liothyronine Sodium | 169 | 62 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 164 | 56 |
| Trazodone Hcl | Trazodone Hcl | 164 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 163 | 69 |
| Ropinirole Hcl | Ropinirole Hcl | 155 | 89 |
| Metformin Hcl | Metformin Hcl | 153 | 53 |
| Mounjaro | Tirzepatide | 120 | 30 |
| Allopurinol | Allopurinol | 119 | 40 |
| Finasteride | Finasteride | 115 | 36 |
| Furosemide | Furosemide | 104 | 42 |
| Gabapentin | Gabapentin | 103 | 45 |
| Spironolactone | Spironolactone | 102 | 40 |
| Simvastatin | Simvastatin | 101 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 35 |
| Omeprazole | Omeprazole | 98 | 36 |
| Carvedilol | Carvedilol | 97 | 29 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 97 | 31 |
| Famotidine | Famotidine | 95 | 39 |
| Alprazolam | Alprazolam | 91 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 83 | 70 |
| Lorazepam | Lorazepam | 80 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 68 | 23 |
| Nebivolol Hcl | Nebivolol Hcl | 68 | 26 |
| Ezetimibe | Ezetimibe | 60 | 18 |
| Azelastine Hcl | Azelastine Hcl | 56 | 24 |
| Eliquis | Apixaban | 55 | 13 |
| Potassium Chloride | Potassium Chloride | 55 | 22 |
| Tramadol Hcl | Tramadol Hcl | 55 | 19 |
| Synthroid | Levothyroxine Sodium | 54 | 17 |
| Farxiga | Dapagliflozin Propanediol | 50 | 14 |
| Jardiance | Empagliflozin | 48 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 20 |
| Mupirocin | Mupirocin | 44 | 30 |
| Sertraline Hcl | Sertraline Hcl | 41 | 12 |
| Clonazepam | Clonazepam | 40 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | suppressed |
| Meloxicam | Meloxicam | 39 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 11 |
| Celecoxib | Celecoxib | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 32 |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Niacin Er | Niacin | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 29 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Pregabalin | Pregabalin | 26 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | 11 |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 20 |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 20 |
| Atenolol | Atenolol | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 13 |
| Valsartan | Valsartan | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 15 |
| Naproxen | Naproxen | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 12 |
| Primidone | Primidone | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,567.32 · 97 records | Amgen Inc. | ABRYSVO, AFREZZA, AREXVY, BREZTRI, CATALYFT PL EXPANDABLE INTERBODY SYSTEM, COMIRNATY, Dexcom G6 Transmitter, EVENITY, FARXIGA, Flexitouch Plus, GEMTESA, GVOKE HYPOPEN, JARDIANCE, Kerendia, Korlym, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, NUZYRA, Nimbl, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, PROLIA, REPATHA, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error